Cytokines in inflammatory bowel disease (original) (raw)

• Danese, S. & Fiocchi, C. Ulcerative colitis. New Engl. J. Med. 365, 1713–1725 (2011).
  Article CAS PubMed Google Scholar
• Baumgart, D. C. & Sandborn, W. J. Crohn's disease. Lancet 380, 1590–1605 (2012).
  Article PubMed Google Scholar
• Strober, W., Fuss, I. J. & Blumberg, R. S. The immunology of mucosal models of inflammation. Annu. Rev. Immunol. 20, 495–549 (2002).
  Article CAS PubMed Google Scholar
• Powrie, F. et al. Inhibition of Th1 responses prevents inflammatory bowel disease in scid mice reconstituted with CD45RBhi CD4+ T cells. Immunity 1, 553–562 (1994). This groundbreaking study defines cytokines as therapeutic targets in chronic intestinal inflammation.
  Article CAS PubMed Google Scholar
• Neurath, M. F., Finotto, S. & Glimcher, L. H. The role of Th1/Th2 polarization in mucosal immunity. Nature Med. 8, 567–573 (2002).
  Article CAS PubMed Google Scholar
• Ruffolo, C. et al. Subclinical intestinal inflammation in patients with Crohn's disease following bowel resection: a smoldering fire. J. Gastrointestinal Surg. 14, 24–31 (2010).
  Article Google Scholar
• Peyrin-Biroulet, L., Loftus, E. V. Jr., Colombel, J. F. & Sandborn, W. J. Long-term complications, extraintestinal manifestations, and mortality in adult Crohn's disease in population-based cohorts. Inflamm. Bowel Dis. 17, 471–478 (2011).
  Article PubMed Google Scholar
• Becker, C. et al. TGF-β suppresses tumor progression in colon cancer by inhibition of IL-6 _trans_-signaling. Immunity 21, 491–501 (2004). This study identifies cytokines as a link between inflammation and tumour growth in experimental models of colitis.
  Article CAS PubMed Google Scholar
• Ebert, E. C., Wright, S. H., Lipshutz, W. H. & Hauptman, S. P. T-cell abnormalities in inflammatory bowel disease are mediated by interleukin 2. Clin. Immunol. Immunopathol. 33, 232–244 (1984).
  Article CAS PubMed Google Scholar
• Mitsuyama, K., Sata, M. & Tanikawa, K. Significance of interleukin-6 in patients with inflammatory bowel disease. Gastroenterol. Japon. 26, 20–28 (1991).
  Article CAS Google Scholar
• Neurath, M. F., Fuss, I., Kelsall, B. L., Stuber, E. & Strober, W. Antibodies to interleukin 12 abrogate established experimental colitis in mice. J. Exp. Med. 182, 1281–1290 (1995).
  Article CAS PubMed Google Scholar
• Jostins, L. et al. Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease. Nature 491, 119–124 (2012).
  Article CAS PubMed PubMed Central Google Scholar
• Kotlarz, D. et al. Loss of interleukin-10 signaling and infantile inflammatory bowel disease: implications for diagnosis and therapy. Gastroenterology 143, 347–355 (2012).
  Article CAS PubMed Google Scholar
• Tilg, H., Ulmer, H., Kaser, A. & Weiss, G. Role of IL-10 for induction of anemia during inflammation. J. Immunol. 169, 2204–2209 (2002).
  Article CAS PubMed Google Scholar
• Herrlinger, K. R. et al. Randomized, double blind controlled trial of subcutaneous recombinant human interleukin-11 versus prednisolone in active Crohn's disease. Am. J. Gastroenterol. 101, 793–797 (2006).
  Article CAS PubMed Google Scholar
• Musch, E. et al. Interferon-β-1a for the treatment of steroid-refractory ulcerative colitis: a randomized, double-blind, placebo-controlled trial. Clin. Gastroenterol. Hepatol. 3, 581–586 (2005).
  Article CAS PubMed Google Scholar
• van Dullemen, H. M. et al. Treatment of Crohn's disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2). Gastroenterology 109, 129–135 (1995). This study identifies TNF as new therapeutic target in patients with Crohn's disease.
  Article CAS PubMed Google Scholar
• Danese, S., Colombel, J. F., Peyrin-Biroulet, L., Rutgeerts, P. & Reinisch, W. Review article: the role of anti-TNF in the management of ulcerative colitis — past, present and future. Aliment. Pharmacol. Ther. 37, 855–866 (2013).
  Article CAS PubMed Google Scholar
• Neurath, M. F. & Travis, S. P. Mucosal healing in inflammatory bowel diseases: a systematic review. Gut 61, 1619–1635 (2012).
  Article CAS PubMed Google Scholar
• Reinisch, W. et al. A dose escalating, placebo controlled, double blind, single dose and multidose, safety and tolerability study of fontolizumab, a humanised anti-interferon γ antibody, in patients with moderate to severe Crohn's disease. Gut 55, 1138–1144 (2006).
  Article CAS PubMed PubMed Central Google Scholar
• Hueber, W. et al. Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial. Gut 61, 1693–1700 (2012). This article reveals the unexpected aggravation of Crohn's disease upon neutralization of IL-17A.
  Article CAS PubMed Google Scholar
• Ng, S. C. et al. Relationship between human intestinal dendritic cells, gut microbiota, and disease activity in Crohn's disease. Inflamm. Bowel Dis 17, 2027–2037 (2011).
  Article CAS PubMed Google Scholar
• Casini-Raggi, V. et al. Mucosal imbalance of IL-1 and IL-1 receptor antagonist in inflammatory bowel disease. A novel mechanism of chronic intestinal inflammation. J. Immunol. 154, 2434–2440 (1995).
  CAS PubMed Google Scholar
• Coccia, M. et al. IL-1β mediates chronic intestinal inflammation by promoting the accumulation of IL-17A secreting innate lymphoid cells and CD4+ Th17 cells. J. Exp. Med. 209, 1595–1609 (2012).
  Article CAS PubMed PubMed Central Google Scholar
• Cominelli, F. et al. Interleukin 1 (IL-1) gene expression, synthesis, and effect of specific IL-1 receptor blockade in rabbit immune complex colitis. J. Clin. Invest. 86, 972–980 (1990).
  Article CAS PubMed PubMed Central Google Scholar
• Kojouharoff, G. et al. Neutralization of tumour necrosis factor (TNF) but not of IL-1 reduces inflammation in chronic dextran sulphate sodium-induced colitis in mice. Clin. Exp. Immunol. 107, 353–358 (1997).
  Article CAS PubMed PubMed Central Google Scholar
• Pizarro, T. T. et al. IL-18, a novel immunoregulatory cytokine, is up-regulated in Crohn's disease: expression and localization in intestinal mucosal cells. J. Immunol. 162, 6829–6835 (1999).
  CAS PubMed Google Scholar
• Kanai, T. et al. Macrophage-derived IL-18-mediated intestinal inflammation in the murine model of Crohn's disease. Gastroenterology 121, 875–888 (2001).
  Article CAS PubMed Google Scholar
• Siegmund, B. et al. Neutralization of interleukin-18 reduces severity in murine colitis and intestinal IFN-γ and TNF-α production. Am. J. Physiol. Regul. Integr. Comp. Physiol. 281, R1264–R1273 (2001).
  Article CAS PubMed Google Scholar
• Atreya, R. et al. Blockade of interleukin 6 trans signaling suppresses T-cell resistance against apoptosis in chronic intestinal inflammation: evidence in crohn disease and experimental colitis in vivo. Nature Med. 6, 583–588 (2000).
  Article CAS PubMed Google Scholar
• Kai, Y. et al. Colitis in mice lacking the common cytokine receptor γ chain is mediated by IL-6-producing CD4+ T cells. Gastroenterology 128, 922–934 (2005).
  Article CAS PubMed Google Scholar
• Ogino, T. et al. Increased Th17-inducing activity of CD14+ CD163 low myeloid cells in intestinal lamina propria of patients with Crohn's disease. Gastroenterology 145, 1380–1391 (2013).
  Article CAS PubMed Google Scholar
• Kamada, N. et al. Unique CD14 intestinal macrophages contribute to the pathogenesis of Crohn disease via IL-23/IFN-γ axis. J. Clin. Invest. 118, 2269–2280 (2008).
  CAS PubMed PubMed Central Google Scholar
• Yamamoto, M., Yoshizaki, K., Kishimoto, T. & Ito, H. IL-6 is required for the development of Th1 cell-mediated murine colitis. J. Immunol. 164, 4878–4882 (2000).
  Article CAS PubMed Google Scholar
• Ito, H. et al. A pilot randomized trial of a human anti-interleukin-6 receptor monoclonal antibody in active Crohn's disease. Gastroenterology 126, 989–996 (2004).
  Article CAS PubMed Google Scholar
• Atreya, R. et al. Antibodies against tumor necrosis factor (TNF) induce T-cell apoptosis in patients with inflammatory bowel diseases via TNF receptor 2 and intestinal CD14+ macrophages. Gastroenterology 141, 2026–2038 (2011).
  Article CAS PubMed Google Scholar
• Su, L. et al. TNFR2 activates MLCK-dependent tight junction dysregulation to cause apoptosis-mediated barrier loss and experimental colitis. Gastroenterology 145, 407–415 (2013).
  Article CAS PubMed Google Scholar
• Di Sabatino, A. et al. Functional modulation of Crohn's disease myofibroblasts by anti-tumor necrosis factor antibodies. Gastroenterology 133, 137–149 (2007). This study defines myofibroblasts as an important target of TNF signalling in IBD.
  Article CAS PubMed Google Scholar
• Gunther, C. et al. Caspase-8 regulates TNF-α-induced epithelial necroptosis and terminal ileitis. Nature 477, 335–339 (2011).
  Article CAS PubMed PubMed Central Google Scholar
• Meijer, M. J. et al. Effect of the anti-tumor necrosis factor-α antibody infliximab on the ex vivo mucosal matrix metalloproteinase-proteolytic phenotype in inflammatory bowel disease. Inflamm.Bowel Dis 13, 200–210 (2007).
  Article PubMed Google Scholar
• Holtmann, M. H. et al. Tumor necrosis factor-receptor 2 is up-regulated on lamina propria T cells in Crohn's disease and promotes experimental colitis in vivo. Eur. J. Immunol. 32, 3142–3151 (2002).
  Article CAS PubMed Google Scholar
• Perrier, C. et al. Neutralization of membrane TNF, but not soluble TNF, is crucial for the treatment of experimental colitis. Inflamm. Bowel Dis 19, 246–253 (2013).
  Article PubMed Google Scholar
• Van den Brande, J. M. et al. Prediction of antitumour necrosis factor clinical efficacy by real-time visualisation of apoptosis in patients with Crohn's disease. Gut 56, 509–517 (2007).
  Article CAS PubMed Google Scholar
• Van den Brande, J. M. et al. Infliximab but not etanercept induces apoptosis in lamina propria T-lymphocytes from patients with Crohn's disease. Gastroenterology 124, 1774–1785 (2003).
  Article CAS PubMed Google Scholar
• Monteleone, G. et al. Interleukin 12 is expressed and actively released by Crohn's disease intestinal lamina propria mononuclear cells. Gastroenterology 112, 1169–1178 (1997).
  Article CAS PubMed Google Scholar
• Liu, Z. et al. The increased expression of IL-23 in inflammatory bowel disease promotes intraepithelial and lamina propria lymphocyte inflammatory responses and cytotoxicity. J. Leukoc. Biol. 89, 597–606 (2011).
  Article CAS PubMed Google Scholar
• Uhlig, H. H. et al. Differential activity of IL-12 and IL-23 in mucosal and systemic innate immune pathology. Immunity 25, 309–318 (2006).
  Article CAS PubMed Google Scholar
• Yen, D. et al. IL-23 is essential for T cell-mediated colitis and promotes inflammation via IL-17 and IL-6. J. Clin. Invest. 116, 1310–1316 (2006).
  Article CAS PubMed PubMed Central Google Scholar
• Ahern, P. P. et al. Interleukin-23 drives intestinal inflammation through direct activity on T cells. Immunity 33, 279–288 (2010).
  Article CAS PubMed PubMed Central Google Scholar
• Izcue, A. et al. Interleukin-23 restrains regulatory T cell activity to drive T cell-dependent colitis. Immunity 28, 559–570 (2008).
  Article CAS PubMed PubMed Central Google Scholar
• Mannon, P. J. et al. Anti-interleukin-12 antibody for active Crohn's disease. New Engl. J. Med. 351, 2069–2079 (2004).
  Article CAS PubMed Google Scholar
• Sandborn, W. J. et al. Ustekinumab induction and maintenance therapy in refractory Crohn's disease. New Engl. J. Med. 367, 1519–1528 (2012). This large clinical trial reports the use of anti-p40 antibodies in patients with Crohn's disease who are refractory to anti-TNF therapy.
  Article CAS PubMed Google Scholar
• Villarino, A. V. et al. IL-27R deficiency delays the onset of colitis and protects from helminth-induced pathology in a model of chronic IBD. Int. Immunol. 20, 739–752 (2008).
  Article CAS PubMed Google Scholar
• Cox, J. H. et al. IL-27 promotes T cell-dependent colitis through multiple mechanisms. J. Exp. Med. 208, 115–123 (2011).
  Article CAS PubMed PubMed Central Google Scholar
• Visperas, A., Do, J. S., Bulek, K., Li, X. & Min, B. IL-27, targeting antigen-presenting cells, promotes Th17 differentiation and colitis in mice. Mucosal Immunol. http://dx.doi.org/10.1038/mi.2013.82 (2013).
• Hanson, M. L. et al. Oral delivery of IL-27 recombinant bacteria attenuates immune colitis in mice. Gastroenterology 146, 210–221 (2014).
  Article CAS PubMed Google Scholar
• Wirtz, S., Billmeier, U., McHedlidze, T., Blumberg, R. S. & Neurath, M. F. Interleukin-35 mediates mucosal immune responses that protect against T-cell-dependent colitis. Gastroenterology 141, 1875–1886 (2011).
  Article CAS PubMed Google Scholar
• Troy, A. E. et al. IL-27 regulates homeostasis of the intestinal CD4+ effector T cell pool and limits intestinal inflammation in a murine model of colitis. J. Immunol. 183, 2037–2044 (2009).
  Article CAS PubMed Google Scholar
• Kole, A. et al. Type I IFNs regulate effector and regulatory T cell accumulation and anti-inflammatory cytokine production during T cell-mediated colitis. J. Immunol. 191, 2771–2779 (2013).
  Article CAS PubMed Google Scholar
• Katakura, K. et al. Toll-like receptor 9-induced type I IFN protects mice from experimental colitis. J. Clin. Invest. 115, 695–702 (2005).
  Article CAS PubMed PubMed Central Google Scholar
• Musch, E. et al. Topical treatment with the Toll-like receptor agonist DIMS0150 has potential for lasting relief of symptoms in patients with chronic active ulcerative colitis by restoring glucocorticoid sensitivity. Inflamm. Bowel Dis 19, 283–292 (2013).
  Article PubMed Google Scholar
• Buonocore, S. et al. Innate lymphoid cells drive interleukin-23-dependent innate intestinal pathology. Nature 464, 1371–1375 (2010). This article highlights innate lymphoid cells as key cytokine producers in experimentally induced colitis.
  Article CAS PubMed PubMed Central Google Scholar
• Geremia, A. et al. IL-23-responsive innate lymphoid cells are increased in inflammatory bowel disease. J. Exp. Med. 208, 1127–1133 (2011).
  Article CAS PubMed PubMed Central Google Scholar
• Bernink, J. H. et al. Human type 1 innate lymphoid cells accumulate in inflamed mucosal tissues. Nature Immunol. 14, 221–229 (2013).
  Article CAS Google Scholar
• Schulthess, J. et al. Interleukin-15-dependent NKp46+ innate lymphoid cells control intestinal inflammation by recruiting inflammatory monocytes. Immunity 37, 108–121 (2012).
  Article CAS PubMed Google Scholar
• Fuchs, A. et al. Intraepithelial type 1 innate lymphoid cells are a unique subset of IL-12- and IL-15-responsive IFN-γ-producing cells. Immunity 38, 769–781 (2013).
  Article CAS PubMed PubMed Central Google Scholar
• Bishop, J. L. et al. Lyn activity protects mice from DSS colitis and regulates the production of IL-22 from innate lymphoid cells. Mucosal Immunol. 7, 405–416 (2014).
  Article CAS PubMed Google Scholar
• Sugimoto, K. et al. IL-22 ameliorates intestinal inflammation in a mouse model of ulcerative colitis. J. Clin. Invest. 118, 534–544 (2008).
  CAS PubMed PubMed Central Google Scholar
• Mielke, L. A. et al. Retinoic acid expression associates with enhanced IL-22 production by γδ T cells and innate lymphoid cells and attenuation of intestinal inflammation. J. Exp. Med. 210, 1117–1124 (2013).
  Article CAS PubMed PubMed Central Google Scholar
• Monteleone, I. et al. Aryl hydrocarbon receptor-induced signals up-regulate IL-22 production and inhibit inflammation in the gastrointestinal tract. Gastroenterology 141, 237–248 (2011).
  Article CAS PubMed Google Scholar
• Zindl, C. L. et al. IL-22-producing neutrophils contribute to antimicrobial defense and restitution of colonic epithelial integrity during colitis. Proc. Natl Acad. Sci. USA 110, 12768–12773 (2013).
  Article PubMed PubMed Central Google Scholar
• Pickert, G. et al. STAT3 links IL-22 signaling in intestinal epithelial cells to mucosal wound healing. J. Exp. Med. 206, 1465–1472 (2009).
  Article CAS PubMed PubMed Central Google Scholar
• Eken, A., Singh, A. K., Treuting, P. M. & Oukka, M. IL-23R+ innate lymphoid cells induce colitis via interleukin-22-dependent mechanism. Mucosal Immunol. 7, 143–154 (2014).
  Article CAS PubMed Google Scholar
• Fuss, I. J. et al. Disparate CD4+ lamina propria (LP) lymphokine secretion profiles in inflammatory bowel disease. Crohn's disease LP cells manifest increased secretion of IFN-γ, whereas ulcerative colitis LP cells manifest increased secretion of IL-5. J. Immunol. 157, 1261–1270 (1996). This is a systematic study of the differences between the cytokine profiles of Crohn's disease and ulcerative colitis.
  CAS PubMed Google Scholar
• Mudter, J. et al. The transcription factor IFN regulatory factor-4 controls experimental colitis in mice via T cell-derived IL-6. J. Clin. Invest. 118, 2415–2426 (2008).
  CAS PubMed PubMed Central Google Scholar
• Weigmann, B. et al. The transcription factor NFATc2 controls IL-6-dependent T cell activation in experimental colitis. J. Exp. Med. 205, 2099–2110 (2008).
  Article CAS PubMed PubMed Central Google Scholar
• Fais, S. et al. Spontaneous release of interferon-γ by intestinal lamina propria lymphocytes in Crohn's disease. Kinetics of in vitro response to interferon γ inducers. Gut 32, 403–407 (1991).
  Article CAS PubMed PubMed Central Google Scholar
• Breese, E., Braegger, C. P., Corrigan, C. J., Walker-Smith, J. A. & MacDonald, T. T. Interleukin-2- and interferon-γ-secreting T cells in normal and diseased human intestinal mucosa. Immunology 78, 127–131 (1993).
  CAS PubMed PubMed Central Google Scholar
• Sakuraba, A. et al. Th1/Th17 immune response is induced by mesenteric lymph node dendritic cells in Crohn's disease. Gastroenterology 137, 1736–1745 (2009).
  Article CAS PubMed Google Scholar
• Parrello, T. et al. Up-regulation of the IL-12 receptor β 2 chain in Crohn's disease. J. Immunol. 165, 7234–7239 (2000).
  Article CAS PubMed Google Scholar
• Neurath, M. F. et al. The transcription factor T-bet regulates mucosal T cell activation in experimental colitis and Crohn's disease. J. Exp. Med. 195, 1129–1143 (2002).
  Article CAS PubMed PubMed Central Google Scholar
• Szabo, S. J. et al. Distinct effects of T-bet in TH1 lineage commitment and IFN-γ production in CD4 and CD8 T cells. Science 295, 338–342 (2002).
  Article CAS PubMed Google Scholar
• Finotto, S. et al. Development of spontaneous airway changes consistent with human asthma in mice lacking T-bet. Science 295, 336–338 (2002).
  Article CAS PubMed Google Scholar
• Lazarevic, V., Glimcher, L. H. & Lord, G. M. T-bet: a bridge between innate and adaptive immunity. Nature Rev. Immunol. 13, 777–789 (2013).
  Article CAS Google Scholar
• Simpson, S. J. et al. T cell-mediated pathology in two models of experimental colitis depends predominantly on the interleukin 12/Signal transducer and activator of transcription (Stat)-4 pathway, but is not conditional on interferon γ expression by T cells. J. Exp. Med. 187, 1225–1234 (1998).
  Article CAS PubMed PubMed Central Google Scholar
• Wirtz, S. et al. Cutting edge: chronic intestinal inflammation in STAT-4 transgenic mice: characterization of disease and adoptive transfer by TNF- plus IFN-γ-producing CD4+ T cells that respond to bacterial antigens. J. Immunol. 162, 1884–1888 (1999).
  CAS PubMed Google Scholar
• Fuss, I. J. & Strober, W. The role of IL-13 and NK T cells in experimental and human ulcerative colitis. Mucosal Immunol. 1 (Suppl. 1), 31–33 (2008).
  Article CAS Google Scholar
• Heller, F. et al. Interleukin-13 is the key effector Th2 cytokine in ulcerative colitis that affects epithelial tight junctions, apoptosis, and cell restitution. Gastroenterology 129, 550–564 (2005).
  Article CAS PubMed Google Scholar
• Heller, F., Fuss, I. J., Nieuwenhuis, E. E., Blumberg, R. S. & Strober, W. Oxazolone colitis, a Th2 colitis model resembling ulcerative colitis, is mediated by IL-13-producing NK-T cells. Immunity 17, 629–638 (2002).
  Article CAS PubMed Google Scholar
• Camelo, A. et al. Blocking IL-25 signalling protects against gut inflammation in a type-2 model of colitis by suppressing nuocyte and NKT derived IL-13. J. Gastroenterol. 47, 1198–1211 (2012).
  Article CAS PubMed PubMed Central Google Scholar
• Biancheri, P. et al. Absence of a role for interleukin-13 in inflammatory bowel disease. Eur. J. Immunol. 44, 370–385 (2013).
  Article CAS Google Scholar
• Danese, S. et al. Tralokinumab (CAT-354), an interleukin 13 antibody, in moderate to severe ulcerative colitis: A phase 2 randomized placebo-controlled study. Presentation OP011. (European Crohn's and Colitis Organisation meeting, Copenhagen, 2014).
• Ivanov, I. I. et al. Induction of intestinal Th17 cells by segmented filamentous bacteria. Cell 139, 485–498 (2009).
  Article CAS PubMed PubMed Central Google Scholar
• Becker, C. et al. Constitutive p40 promoter activation and IL-23 production in the terminal ileum mediated by dendritic cells. J. Clin. Invest. 112, 693–706 (2003).
  Article CAS PubMed PubMed Central Google Scholar
• Kobayashi, T. et al. IL23 differentially regulates the Th1/Th17 balance in ulcerative colitis and Crohn's disease. Gut 57, 1682–1689 (2008).
  Article CAS PubMed Google Scholar
• Rovedatti, L. et al. Differential regulation of interleukin 17 and interferon γ production in inflammatory bowel disease. Gut 58, 1629–1636 (2009).
  Article CAS PubMed Google Scholar
• Sarra, M. et al. Interferon-γ-expressing cells are a major source of interleukin-21 in inflammatory bowel diseases. Inflamm. Bowel Dis 16, 1332–1339 (2010).
  Article PubMed Google Scholar
• Dambacher, J. et al. The role of the novel Th17 cytokine IL-26 in intestinal inflammation. Gut 58, 1207–1217 (2009).
  Article CAS PubMed Google Scholar
• Kamada, N. et al. TL1A produced by lamina propria macrophages induces Th1 and Th17 immune responses in cooperation with IL-23 in patients with Crohn's disease. Inflamm. Bowel Dis 16, 568–575 (2010).
  Article PubMed Google Scholar
• Kleinschek, M. A. et al. Circulating and gut-resident human Th17 cells express CD161 and promote intestinal inflammation. J. Exp. Med. 206, 525–534 (2009).
  Article CAS PubMed PubMed Central Google Scholar
• Monteleone, G. et al. Control of matrix metalloproteinase production in human intestinal fibroblasts by interleukin 21. Gut 55, 1774–1780 (2006).
  Article CAS PubMed PubMed Central Google Scholar
• Monteleone, G. et al. Interleukin-21 enhances T-helper cell type I signaling and interferon-γ production in Crohn's disease. Gastroenterology 128, 687–694 (2005). This article identifies IL-21 as crucial mediator of immune cell activation in Crohn's disease.
  Article CAS PubMed Google Scholar
• Siakavellas, S. I. & Bamias, G. Role of the IL-23/IL-17 axis in Crohn's disease. Discov. Med. 14, 253–262 (2012).
  PubMed Google Scholar
• Leung, J. M. et al. IL-22-producing CD4+ cells are depleted in actively inflamed colitis tissue. Mucosal Immunol. 7, 124–133 (2013).
  Article CAS PubMed Google Scholar
• O'Connor, W. Jr. et al. A protective function for interleukin 17A in T cell-mediated intestinal inflammation. Nature Immunol. 10, 603–609 (2009).
  Article CAS Google Scholar
• Leppkes, M. et al. RORγ-expressing Th17 cells induce murine chronic intestinal inflammation via redundant effects of IL-17A and IL-17F. Gastroenterology 136, 257–267 (2009).
  Article CAS PubMed Google Scholar
• Zenewicz, L. A. et al. Innate and adaptive interleukin-22 protects mice from inflammatory bowel disease. Immunity 29, 947–957 (2008).
  Article CAS PubMed PubMed Central Google Scholar
• Ono, Y. et al. T-helper 17 and interleukin-17-producing lymphoid tissue inducer-like cells make different contributions to colitis in mice. Gastroenterology 143, 1288–1297 (2012).
  Article CAS PubMed Google Scholar
• Sujino, T. et al. Regulatory T cells suppress development of colitis, blocking differentiation of T-helper 17 into alternative T-helper 1 cells. Gastroenterology 141, 1014–1023 (2011).
  Article CAS PubMed Google Scholar
• Reinisch, W. et al. Fontolizumab in moderate to severe Crohn's disease: a phase 2, randomized, double-blind, placebo-controlled, multiple-dose study. Inflamm. Bowel Dis 16, 233–242 (2010).
  Article PubMed Google Scholar
• Asseman, C., Mauze, S., Leach, M. W., Coffman, R. L. & Powrie, F. An essential role for interleukin 10 in the function of regulatory T cells that inhibit intestinal inflammation. J. Exp. Med. 190, 995–1004 (1999).
  Article CAS PubMed PubMed Central Google Scholar
• Powrie, F., Carlino, J., Leach, M. W., Mauze, S. & Coffman, R. L. A critical role for transforming growth factor-β but not interleukin 4 in the suppression of T helper type 1-mediated colitis by CD45RBlow CD4+ T cells. J. Exp. Med. 183, 2669–2674 (1996).
  Article CAS PubMed Google Scholar
• Huber, S. et al. Th17 cells express interleukin-10 receptor and are controlled by Foxp3− and Foxp3+ regulatory CD4+ T cells in an interleukin-10-dependent manner. Immunity 34, 554–565 (2011).
  Article CAS PubMed PubMed Central Google Scholar
• Davidson, N. J. et al. T helper cell 1-type CD4+ T cells, but not B cells, mediate colitis in interleukin 10-deficient mice. J. Exp. Med. 184, 241–251 (1996).
  Article CAS PubMed Google Scholar
• Marie, J. C., Liggitt, D. & Rudensky, A. Y. Cellular mechanisms of fatal early-onset autoimmunity in mice with the T cell-specific targeting of transforming growth factor-β receptor. Immunity 25, 441–454 (2006).
  Article CAS PubMed Google Scholar
• Li, M. O., Sanjabi, S. & Flavell, R. A. Transforming growth factor-β controls development, homeostasis, and tolerance of T cells by regulatory T cell-dependent and -independent mechanisms. Immunity 25, 455–471 (2006).
  Article CAS PubMed Google Scholar
• Chaudhry, A. et al. CD4+ regulatory T cells control TH17 responses in a Stat3-dependent manner. Science 326, 986–991 (2009).
  Article CAS PubMed PubMed Central Google Scholar
• Maynard, C. L. et al. Regulatory T cells expressing interleukin 10 develop from Foxp3+ and Foxp3− precursor cells in the absence of interleukin 10. Nature Immunol. 8, 931–941 (2007).
  Article CAS Google Scholar
• Smith, P. M. et al. The microbial metabolites, short-chain fatty acids, regulate colonic Treg cell homeostasis. Science 341, 569–573 (2013).
  Article CAS PubMed Google Scholar
• Monteleone, G. et al. Blocking Smad7 restores TGF-β1 signaling in chronic inflammatory bowel disease. J. Clin. Invest. 108, 601–609 (2001). This report describes a rational strategy to target TGFβ signalling in IBD that has led to clinical trials using SMAD7 antisense DNA.
  Article CAS PubMed PubMed Central Google Scholar
• Fantini, M. C. et al. Smad7 controls resistance of colitogenic T cells to regulatory T cell-mediated suppression. Gastroenterology 136, 1308–1316 (2009).
  Article CAS PubMed Google Scholar
• Rani, R., Smulian, A. G., Greaves, D. R., Hogan, S. P. & Herbert, D. R. TGF-β limits IL-33 production and promotes the resolution of colitis through regulation of macrophage function. Eur. J. Immunol. 41, 2000–2009 (2011).
  Article CAS PubMed PubMed Central Google Scholar
• Monteleone, G. et al. Phase I clinical trial of Smad7 knockdown using antisense oligonucleotide in patients with active Crohn's disease. Mol. Ther. 20, 870–876 (2012).
  Article CAS PubMed PubMed Central Google Scholar
• Maul, J. et al. Peripheral and intestinal regulatory CD4+ CD25high T cells in inflammatory bowel disease. Gastroenterology 128, 1868–1878 (2005).
  CAS PubMed Google Scholar
• Desreumaux, P. et al. Safety and efficacy of antigen-specific regulatory T-cell therapy for patients with refractory Crohn's disease. Gastroenterology 143, 1207–1217.e2 (2012). This is the first report of the use of regulatory T cells as a therapy for Crohn's disease.
  Article CAS PubMed Google Scholar
• Pastorelli, L. et al. Epithelial-derived IL-33 and its receptor ST2 are dysregulated in ulcerative colitis and in experimental Th1/Th2 driven enteritis. Proc. Natl Acad. Sci. USA 107, 8017–8022 (2010).
  Article CAS PubMed PubMed Central Google Scholar
• Gross, P., Doser, K., Falk, W., Obermeier, F. & Hofmann, C. IL-33 attenuates development and perpetuation of chronic intestinal inflammation. Inflamm. Bowel Dis 18, 1900–1909 (2012).
  Article Google Scholar
• Oboki, K. et al. IL-33 is a crucial amplifier of innate rather than acquired immunity. Proc. Natl Acad. Sci. USA 107, 18581–18586 (2010).
  Article PubMed PubMed Central Google Scholar
• Sedhom, M. A. et al. Neutralisation of the interleukin-33/ST2 pathway ameliorates experimental colitis through enhancement of mucosal healing in mice. Gut 62, 1714–1723 (2013).
  Article CAS PubMed Google Scholar
• Imaeda, H. et al. Epithelial expression of interleukin-37b in inflammatory bowel disease. Clin. Exp. Immunol. 172, 410–416 (2013).
  Article CAS PubMed PubMed Central Google Scholar
• McNamee, E. N. et al. Interleukin 37 expression protects mice from colitis. Proc. Natl Acad. Sci. USA 108, 16711–16716 (2011).
  Article PubMed PubMed Central Google Scholar
• Nava, P. et al. Interferon-γ regulates intestinal epithelial homeostasis through converging β-catenin signaling pathways. Immunity 32, 392–402 (2010).
  Article CAS PubMed PubMed Central Google Scholar
• Neufert, C. et al. Tumor fibroblast-derived epiregulin promotes growth of colitis-associated neoplasms through ERK. J. Clin. Invest. 123, 1428–1443 (2013).
  Article CAS PubMed PubMed Central Google Scholar
• Grivennikov, S. et al. IL-6 and Stat3 are required for survival of intestinal epithelial cells and development of colitis-associated cancer. Cancer Cell 15, 103–113 (2009).
  Article CAS PubMed PubMed Central Google Scholar
• Bollrath, J. et al. gp130-mediated Stat3 activation in enterocytes regulates cell survival and cell-cycle progression during colitis-associated tumorigenesis. Cancer Cell 15, 91–102 (2009).
  Article CAS PubMed Google Scholar
• Garrett, W. S. et al. Colitis-associated colorectal cancer driven by T-bet deficiency in dendritic cells. Cancer Cell 16, 208–219 (2009). This article links cytokines produced by innate immune cells to tumour development in intestinal inflammation.
  Article CAS PubMed PubMed Central Google Scholar
• Greten, F. R. et al. IKKβ links inflammation and tumorigenesis in a mouse model of colitis-associated cancer. Cell 118, 285–296 (2004).
  Article CAS PubMed Google Scholar
• Wang, Y. et al. Neutrophil infiltration favors colitis-associated tumorigenesis by activating the interleukin-1 (IL-1)/IL-6 axis. Mucosal Immunol. http://dx.doi.org/10.1038/mi.2013.126 (2014).
• Popivanova, B. K. et al. Blocking TNF-α in mice reduces colorectal carcinogenesis associated with chronic colitis. J. Clin. Invest. 118, 560–570 (2008).
  CAS PubMed PubMed Central Google Scholar
• Gerlach, K. et al. Transcription factor NFATc2 controls the emergence of colon cancer associated with IL-6- dependent colitis. Cancer Res. 72, 4340–4350 (2012).
  Article CAS PubMed Google Scholar
• Kirchberger, S. et al. Innate lymphoid cells sustain colon cancer through production of interleukin-22 in a mouse model. J. Exp. Med. 210, 917–931 (2013).
  Article CAS PubMed PubMed Central Google Scholar
• Stolfi, C. et al. Involvement of interleukin-21 in the regulation of colitis-associated colon cancer. J. Exp. Med. 208, 2279–2290 (2011).
  Article CAS PubMed PubMed Central Google Scholar
• Huber, S. et al. IL-22BP is regulated by the inflammasome and modulates tumorigenesis in the intestine. Nature 491, 259–263 (2012).
  Article CAS PubMed PubMed Central Google Scholar
• Sandborn, W. J. et al. Tofacitinib, an oral Janus kinase inhibitor, in active ulcerative colitis. New Engl. J. Med. 367, 616–624 (2012). This is the first report of the use of a JAK multi-cytokine blocker for the treatment of IBD.
  Article CAS PubMed Google Scholar
• Zorzi, F. et al. Distinct profiles of effector cytokines mark the different phases of Crohn's disease. PLoS ONE 8, e54562 (2013).
  Article CAS PubMed PubMed Central Google Scholar
• Verdier, J., Begue, B., Cerf-Bensussan, N. & Ruemmele, F. M. Compartmentalized expression of Th1 and Th17 cytokines in pediatric inflammatory bowel diseases. Inflamm. Bowel Dis 18, 1260–1266 (2012).
  Article CAS PubMed Google Scholar
• Hovhannisyan, Z., Treatman, J., Littman, D. R. & Mayer, L. Characterization of interleukin-17-producing regulatory T cells in inflamed intestinal mucosa from patients with inflammatory bowel diseases. Gastroenterology 140, 957–965 (2011).
  Article CAS PubMed Google Scholar
• Atreya, R. et al. In vivo molecular imaging using fluorescent anti-TNF antibodies predicts response to biological therapy in Crohn's disease. Nature Med. 20, 313–318 (2014). This is the first study to use molecular in vivo imaging of TNF in Crohn's disease.
  Article CAS PubMed Google Scholar
• Sandborn, W. J. et al. A phase 2 study of Tofacitinib, an oral janus kinase inhibitor, in patients with Crohn's disease. Clin. Gastroenterol. Hepatol. http://dx.doi.org/10.1016/j.cgh.2014.01.029 (2014).
• Morrison, S. L. Two heads are better than one. Nature Biotech. 25, 1233–1234 (2007).
  Article CAS Google Scholar
• Vandenbroucke, K. et al. Orally administered L. lactis secreting an anti-TNF Nanobody demonstrate efficacy in chronic colitis. Mucosal Immunol. 3, 49–56 (2010).
  Article CAS PubMed Google Scholar